AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04741698 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propranolol
Description: Propranolol 2mg IV
Study NCT04758910 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High Flow Oxygen Therapy
Description: A 30-minute spontaneous breathing trial using high flow oxygen therapy via tracheostomy.
Study NCT04758910 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: T-piece
Description: A 30-minute spontaneous breathing trial using T-piece via tracheostomy.
Study NCT05391542 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: aligning archwires
Description: At the day of bonding, 0.016-inch archwire will be placed for the TuNT group. Eight weeks later it will be replaced by the 0.018-inch archwire for another eight weeks. While, for the CuNT group, 0.014-inch archwire will be placed at the day of bonding and eight weeks later it will be replaced by the 0.018-inch archwire for another eight weeks. Archwires will be tied to the bracket by elastomeric modules which will be changed every 4 weeks. A good-quality alginate impression for the lower arch should be taken pre-treatment and after 4, 8, 12 and 16 weeks and a stone study model is obtained. Periapical X-ray for the mandibular central incisors will be taken pre-treatment and after 16 weeks. The participants will be provided by a visual analog scale (0-10) to record their pain perception during the first week after each wire placement.
Study NCT05542303 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZB001 for injection
Description: Dose Cohort3 (20mg/kg) ZB001 of single IV injection
Study NCT05167149 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Carbon nanoparticles
Description: After pneumoperitoneum is established and laparoscopic instruments are prepared, according to National Comprehensive Cancer Network (NCCN) guidelines, 1ml diluted ICG solution (25 mg /10 ml) is injected into the submucosa around tumor at 3 and 9 o'clock of the cervix (2ml totally) with 1ml syringe. ICG should be slowly injected to avoid drug leakage. Intratumoral and deep cervical stroma injection should be avoided. The retroperitoneum is dissected immediately after injection under the multimodel observation of fluorescence laparoscopy. Search the fluorescent labeled lymphatics from bilateral parametrium to iliac vessels. The diffusion of ICG is rapid , and it is easy to spread to the next stations lymph nodes. The first fluorescent labeled lymph nodes on each lymphatic drainage pathway are identified as SLNs, other than all fluorescent lymph nodes. All detectable SLNs and enlarged or suspicious nodes regardless of mapping are resected for pathological examination alone.
Study NCT05167149 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Indocyanine green
Description: After pneumoperitoneum is established and laparoscopic instruments are prepared, according to NCCN guidelines, 0.5ml(25mg) carbon nanoparticle solution (the dose was from our retrospective study) is injected into the submucosa around tumor at 3 and 9 o'clock of the cervix (1ml totally) with 1ml syringe. Carbon nanoparticle should be slowly injected to avoid drug leakage. Intratumoral and deep cervical stroma injection should be avoided. The retroperitoneum is dissected immediately after injection. Search the black lymphatics from bilateral parametrium to iliac vessels. Because there is no fluorescence penetration as ICG, the black lymphatic vessels should be dissected carefully.The first black lymph nodes on each lymphatic drainage pathway are identified as SLNs, other than all black lymph nodes. All detectable SLNs and enlarged or suspicious nodes regardless of mapping are resected for pathological examination alone.
Study NCT05302193 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Calm measurement of blood pressure and heart rate (before physical activity)
Description: Simultaneous blood pressure and heart rate measurements at minutes 2 and 5.5 of the experiment.
Study NCT05302193 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical activity
Description: Five minutes of physical activity, between times 7.5 min and 12.5 min of the experimental part. Riding on a spinning ergometer with a standardized load of 1 W/kg.
Study NCT05302193 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Calm measurement of blood pressure and heart rate (after physical activity)
Description: Simultaneous blood pressure and heart rate measurements at times 15.5, 17, 20.5 and 22 minutes of the experimental part.
Study NCT05805488 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo sachet
Description: consume 1 sachet per day
Study NCT05488795 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Team-Based Home Blood Pressure Monitoring
Description: Implementation of best practices for hypertension control using a practice wide team-based home blood pressure monitoring intervention
Study NCT05020808 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: SHAM_COMPARATOR
Intervention: NEAA
Description: Food grade mixture of non-essential amino acids in powdered form to be dissolved in water. Supplied by Marigot Ltd, Cork, Ireland
Study NCT05020808 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: PPI
Description: Food grade plant (legume - Fava) protein isolate to be dissolved in water. Supplied by Marigot Ltd, Cork, Ireland
Study NCT05805488 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: TCI904 sachet
Description: consume 1 sachet per day
Study NCT05388968 — intervention group
Intervention type: BIOLOGICAL
Intervention: Metatranscriptomic
Description: Analysis with metatranscriptomic next generation sequencing of trophoblast obtained by chorionic villi sampling
Study NCT05388968 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Specific microbiologic diagnosis
Description: If a microorganism is detected by metatranscriptomic NGS, specific diagnosis (PCR and serology) will be done in maternal and neonatal samples (blood, urine, saliva)
Study NCT06425341 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-5635 Injection
Description: HRS-5635 Injection low dose administered by subcutaneous injection
Study NCT06425341 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-5635 Injection
Description: HRS-5635 Injection medium dose administered by subcutaneous injection
Study NCT06425341 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-5635 Injection
Description: HRS-5635 Injection high dose administered by subcutaneous injection
Study NCT06425341 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-5635 Injection
Description: HRS-5635 Injection lowest dose administered by subcutaneous injection
Study NCT05638217 — intervention group
Intervention type: COMBINATION_PRODUCT
Intervention: Silver diamine fluoride 38% followed by Sodium fluoride varnish 5%
Description: 1)Completely drying of the affected area 2)10 microliters of silver diamine fluoride 38% (CaviGuard®) will be placed on the affected area 3)The affected area should be immediately covered with 20 microliters of fluoride varnish 5% (CaviGuard®) 4)Repeat steps 1-3 one or two more times for large caries at intervals of at least 2 days apart 5)Follow up evaluation of treatment success visits will be conducted at 6 and 12 months from the initial treatment.~NOTE: This is a single intervention using the device registered as Caviguard® to apply both products (Silver diamine fluoride 38% followed by Sodium fluoride varnish 5% (®)) in sequence.
Study NCT06427642 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mononuclear cells
Description: UCB-MNCs are obtained from umbilical cord blood by density gradient centrifugation
Study NCT06427642 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mild hypothermia therapy
Description: Mild hypothermia therapy via hypothermia therapy apparatus
Study NCT06427642 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mild hypothermia therapy
Description: Mild hypothermia therapy via hypothermia therapy apparatus
Study NCT06427642 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Breathing support technique
Description: Breathing support via ventilator
Study NCT06427642 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Breathing support technique
Description: Breathing support via ventilator
Study NCT06427642 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total parenteral nutrition
Description: Liquid nutrition injected directly into the bloodstream
Study NCT06427642 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total parenteral nutrition
Description: Liquid nutrition injected directly into the bloodstream
Study NCT05294146 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofazimine
Description: All participants will receive an (experimental) oral loading dose regimen of 300 mg clofazimine once daily (= 3 capsules of 100 mg) for 4 weeks. Afterwards, all participants will continue with a standard oral dose of 100 mg clofazimine once daily (= 1 capsule of 100 mg) until a total 4 months of treatment with CFZ.~Blood samples will be taken at Day 28 (+/- 2 days), Day 29 (Day 28 +1) and after 4 months of treatment to assess the pharmacokinetics of CFZ, both with the loading dose and the standard dose. In addition, the safety/tolerability of CFZ will monitored.
Study NCT06247800 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Virtual Reality Device
Description: A virtual reality headset is a heads-up display that allows users to interact with simulated environment.
Study NCT06247800 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Without virtual reality
Description: Patients undergoing intercostal chest drain without the use VR device
Study NCT05439772 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron
Description: Patient will take one dissolvable tablet of ondansetron prior to initiating PEG consumption.
Study NCT06001385 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Given IV or PO pre-transplant as part of conditioning regimen
Study NCT04681417 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan or Melphalan + Topotecan
Description: IAC: 2-6 cycles every 1 month (number based on the local tumor evolution), performed using radio-guided catheterization and delivery at the ostium of the ophthalmic artery, in neuroradiology operating room, and under General Anesthesia (GA). IAC will be administered at the Fondation Rothschild Hospital in collaboration with the Interventional Neuroradiology team.
Study NCT04681417 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: etoposide, carboplatin and vincristine or local ophthalmological treatment without IV chemotherapy
Description: 2 to 6 cycles of combined etoposide, carboplatin and vincristine or local ophthalmological treatment without IV chemotherapy : thermotherapy and/or cryotherapy and/or iodine-125 plaques and/or intravitreal chemotherapy injections
Study NCT04681417 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Carboplatin administered on Day 1
Description: Chemothermotherapy : Intravenous injection by carboplatin
Study NCT04681417 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thermotherapy (local treatment)
Description: Thermotherapy after carboplatin administered on Day 1
Study NCT04681417 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Thermotherapy (local treatment)
Description: Thermotherapy after carboplatin administered on Day 1
Study NCT04681417 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cryotherapy (local treatment)
Description: Cryotherapy (local treatment)
Study NCT04681417 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Cryotherapy (local treatment)
Description: Cryotherapy (local treatment)
Study NCT04681417 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Iodine-125 plaques (local treatment)
Description: Iodine-125 plaques (local treatment)
Study NCT04681417 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Iodine-125 plaques (local treatment)
Description: Iodine-125 plaques (local treatment)
Study NCT04681417 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravitreal Melphalan chemotherapy injections (local treatment)
Description: Intravitreal Melphalan chemotherapy injections (local treatment)
Study NCT04681417 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Intravitreal Melphalan chemotherapy injections (local treatment)
Description: Intravitreal Melphalan chemotherapy injections (local treatment)
Study NCT05477862 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clinically Designed Improvisatory Music
Description: Clinically Designed Improvisatory Music (CDIM) is a form of improvised music based on calm-inducing sound parameters which brought relief to our cohort of neurology patients.
Study NCT06001385 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Given IV pre-transplant as part of conditioning regimen
Study NCT06357130 — intervention group
Intervention type: OTHER
Intervention: Questionnaire
Description: A flyer with QR code leading to the online questionnaire will be sent to trans associations and healthcare networks for distribution to the target population.
Study NCT04749446 — intervention group
Intervention type: OTHER
Intervention: Treatment of Breast Sarcoma according clinical practice (includes drugs, surgery or any other received treatments)
Description: This observational study collects all the treatments received by the patients according clinical practices or experimental trials and therefore includes drug/biological/surgical and any other applicable treatments~Reorder Outcome Measures
Study NCT05532137 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: e-12HR app
Description: The 'feedback' e-12HR version: This version of the application allows to calculate the Mediterranean Diet Serving Score (MDSS) index; additionally, this version is designed to promote the Mediterranean diet with two specific automatic functions:~1. Evaluation of the user's MDSS index.~2. Identification of the food groups for which the user has not fulfilled the Mediterranean diet recommendations (in addition, this version also provided the user the consumption recommendations established for these food groups).
Study NCT06001385 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PBSC Hematopoietic Stem Cell Transplantation (HSCT)
Description: Peripheral blood stem cell graft is infused from a mismatched unrelated donor on Day 0
Study NCT05236543 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD4831
Description: Subjects will receive single oral dose only on Day 1 and Day 11.
Study NCT05236543 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Subjects will receive Itraconazole orally on Days 8 followed by dosing from Day 9 to Day 17.
Study NCT06483022 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: BELIEVE IPE Training
Description: The IPC training will be delivered to health team members who provide intrapartum and/or postpartum maternity care at each facility. Individuals with roles as maternity care providers, nurses, lactation consultants or doulas whose primary inpatient clinical assignment is maternity care will be included in the training. The training will consist of a pre-session module (about 60 minutes), a 90-minute interprofessional collaboration session, delivered using virtual reality head-sets, and post-session modules (about 60 minutes). The pre- and post-session modules will be delivered through an online learning platform.
Study NCT06483022 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Usual Care
Description: Prior to implementation of the IPC training, birthing people at the facilities will receive treatment-as-usual
Study NCT06001385 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Post-Transplant Cyclophosphamide
Description: Cyclophosphamide (25mg/kg) is administered on Day 3 and Day 4 post-transplant as an IV infusion over 1-2 hours.~First 20 subjects with a 4-6/8 HLA mismatched unrelated donor will receive an intermediate dose of post-transplant cyclophosphamide of 37.5 mg/kg Day 3 and Day 4 post-transplant.
Study NCT06132776 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HiToP 191 PNP
Description: High tone therapy
Study NCT06132776 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo device
Description: Placebo therapy
Study NCT04765202 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: AG Tx
Description: The control treatment is meshed autograft applied to a FT burn area
Study NCT04765202 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SOMA Tx
Description: The experimental treatment is more widely meshed autograft than the AG Tx site applied to a FT burn area and covered with SOMA
Study NCT06001385 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesna
Description: Mesna is given in divided doses IV 30 min pre- and at 3, 6, and 8 hours post cyclophosphamide.
Study NCT06001385 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Tacrolimus is given at a dose of 0.05 mg/kg PO or an IV dose of 0.03 mg/kg of ideal body weight (IBW) starting on Day +5 post-transplant with taper recommended at Day + 90 and finished by Day +180.
Study NCT05696808 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: IHPD
Description: The intervention is planned as a supervised dietary supplementation, with a goal of restricting the calorie intake to 25 Kcal/Kg BW/day, with a protein intake of 1 gm/Kg BW/day i.e., around 15 % of total calories from protein, 35% from fats and 50% from carbohydrates. Major portion of the carbohydrates is vegetables, fruits and then cereals (high fiber cereals), more amount of tomato and amla at least 200 gm in a day, protein requirements are met by mainly legumes like chick pea black - (kala chana) and moong sprouts besides dals. Lean meats and egg whites would be allowed as the non-vegetarian source. Milk products used are only milk and buttermilk, curd (excluding paneer). Major source of oil would be mustard oil only.
Study NCT05696808 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Western Diet
Description: The intervention is planned with a goal of restricting the calorie intake to 40 Kcal/Kg BW/day, around 10-15 % of total calories from protein, 30-35% from fats and 55-60% from carbohydrates. Major portion of the carbohydrates is Western fast food comprising of pizza and burger, French fries, sweets, muffins, cakes, chocolates, sugar sweetened beverages.
Study NCT04381897 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetyl cysteine
Description: Oral solution for N-acetyl cysteine is prepared in syringes and provided to the participants along with instructions on how to administer them.
Study NCT04381897 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: NAC Placebo-matching solution is prepared in syringes and provided to the participants along with instructions on how to administer them.
Study NCT06603402 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: low-dose involved-field radiotherapy combined with immunochemotherapy
Description: low-dose involved-field radiotherapy combined with immunochemotherapy
Study NCT04768686 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FLX475
Description: tablet
Study NCT04768686 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion
Study NCT06001385 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Mycophenolate mofetil (MMF) is given at a dose of 15 mg/kg three times daily IV or PO from Day +5 to Day +35 post-transplant.
Study NCT06001385 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient Reported Outcomes
Description: Survey assessments will be administered to study participants pre transplant, at Day + 100, Day + 180, and Day +365 post transplant.
Study NCT06001385 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Given IV pre transplant as part of conditioning regimen
Study NCT06001385 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total-body irradiation
Description: Administered pre-transplant as part of conditioning regimen
Study NCT06001385 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV pre-transplant as part of conditioning regimen
Study NCT04920318 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: tDCS + language therapy
Description: In this study fMRI-guided noninvasive neuromodulation will be applied, called Transcranial Direct Current Stimulation (tDCS) to the frontal and parietal brain regions that show reduced activation but still are structurally intact. TDCS will be paired with personalized speech-language therapy to enhance language functions.
Study NCT04920318 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: SHAM_COMPARATOR
Intervention: sham TDCS + language therapy
Description: sham control will be applied with language therapy to the same regions as active TDCS.
Study NCT05875805 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telehealth Serious Illness Care Program
Description: The adapted telehealth Serious Illness Care Program is a multilevel intervention engaging the patient, caregiver, clinician, and system. It consists of tools, training, and system change. Tools include: 1) The Serious Illness Conversation Guide for clinicians; and 2) Education materials for patients on the importance of Serious Illness Conversations (Patient Preparation Pamphlet) and of the involvement of caregivers (Family Communication Guide).
Study NCT05875805 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Education Control
Description: Education materials developed by the NCI on Communication in Cancer Care (PDQ®) - Patient Version
Study NCT06262607 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CLE-400
Description: Topical CLE400 gel 0.28% administered once daily